03174nas a2200481 4500000000100000008004100001653001100042653001100053653000900064653000900073653001600082653001000098653001400108653002100122653002800143653002800171653001000199653002600209653002400235653002900259653002700288653003200315653001100347653001100358100001100369700001200380700001600392700001900408700001500427700001200442700002100454700001700475700001400492700001600506700001400522700001400536700001600550245013100566300001300697490000700710520196100717022001402678 2017 d10aFemale10aHumans10aAged10aMale10aMiddle Aged10aChina10aIncidence10aHealth Promotion10aCosts and Cost Analysis10aCardiovascular Diseases10aChild10aCost-Benefit Analysis10aModels, Statistical10aSodium Chloride, Dietary10aSchool Health Services10aQuality-Adjusted Life Years10aEating10aFamily1 aMa Jun1 aLi Xian1 aWu Yangfeng1 aFeng Xiangxian1 aYan Lijing1 aHe Feng1 aMacGregor Graham1 aHayes Alison1 aChu Yunbo1 aWang Haijun1 aNiu Wenyi1 aHan Yanbo1 aJan Stephen00aCost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China. ae01830330 v123 a

OBJECTIVE: The School-based Education Program to Reduce Salt Intake in Children and Their Families study was a cluster randomized control trial among grade five students in 28 primary schools and their families in Changzhi, China. It achieved a significant effect in lowering systolic blood pressure (SBP) in all family adults by 2.3 mmHg and in elderlies (aged > = 60 years) by 9.5 mmHg. The aim of this study was to assess the cost-effectiveness of this salt reduction program.

METHODS: Costs of the intervention were assessed using an ingredients approach to identify resource use. A trial-based incremental cost-effectiveness ratio (ICER) was estimated based on the observed effectiveness in lowering SBP. A Markov model was used to estimate the long-term cost-effectiveness of the intervention, and then based on population data, extrapolated to a scenario where the program is scaled up nationwide. Findings were presented in terms of an incremental cost per quality-adjusted life year (QALY). The perspective was that of the health sector.

RESULTS: The intervention cost Int$19.04 per family and yielded an ICER of Int$2.74 (90% CI: 1.17-12.30) per mmHg reduction of SBP in all participants (combining children and adult participants together) compared with control group. If scaled up nationwide for 10 years and assumed deterioration in treatment effect of 50% over this period, it would reach 165 million families and estimated to avert 42,720 acute myocardial infarction deaths and 107,512 stroke deaths in China. This would represent a gain of 635,816 QALYs over 10-year time frame, translating into Int$1,358 per QALY gained.

CONCLUSION: Based on WHO-CHOICE criteria, our analysis demonstrated that the proposed salt reduction strategy is highly cost-effective, and if scaled up nationwide, the benefits could be substantial.

TRIAL REGISTRATION: ClinicalTrials.gov NCT01821144.

 a1932-6203